Growth Metrics

Boston Scientific (BSX) Liabilities and Shareholders Equity (2016 - 2026)

Boston Scientific's Liabilities and Shareholders Equity history spans 18 years, with the latest figure at $44.4 billion for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 10.49% to $44.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $172.3 billion, a 11.36% increase, with the full-year FY2025 number at $43.7 billion, up 10.86% from a year prior.
  • Liabilities and Shareholders Equity hit $44.4 billion in Q1 2026 for Boston Scientific, up from $43.7 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for BSX hit a ceiling of $44.4 billion in Q1 2026 and a floor of $31.9 billion in Q3 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $37.0 billion across 5 years, with a median of $36.7 billion in 2024.
  • Biggest five-year swings in Liabilities and Shareholders Equity: grew 0.22% in 2022 and later rose 12.16% in 2025.
  • Tracing BSX's Liabilities and Shareholders Equity over 5 years: stood at $32.5 billion in 2022, then grew by 8.21% to $35.1 billion in 2023, then grew by 12.12% to $39.4 billion in 2024, then grew by 10.86% to $43.7 billion in 2025, then grew by 1.55% to $44.4 billion in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for BSX at $44.4 billion in Q1 2026, $43.7 billion in Q4 2025, and $42.7 billion in Q3 2025.